When should I order PrismRA® for my patients?
You can order PrismRA whenever you are considering RA therapy or treatment modifications for your patients. PrismRA identifies patients who are unlikely to respond to TNF inhibitor (TNFi) therapies. It can be used before you prescribe, escalate a dose, or modify treatment. The PrismRA molecular signature test was studied in biologic-naïve and biologic-exposed patients (N=730 patient samples) who had moderate-to-severe RA.1-3
How was PrismRA first validated?
PrismRA was prospectively studied in 175 biologic-naïve patients with RA enrolled in the CorEvitas Comparative Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) study.1 The CERTAIN study is the largest validation and clinical utility study of its kind. Response was defined as ACR50 at 6 months post TNFi initiation. Actual patient outcomes at 6 months were cross-referenced with PrismRA results. PrismRA® identified patients who are unlikely to respond to TNFi therapies with 90% accuracy.1
What is a molecular signature?
Like fingerprints, molecular signatures are unique. They reveal how diseases affect each patient differently. A molecular signature combines a set of biological features to capture an individual’s genetic makeup and disease behavior.1,4,5 These features include RNA, proteins, and other features that reflect a patient’s distinctive disease biology.
How can PrismRA help improve patient outcomes?
PrismRA can impact prescribing decisions by identifying patients who are unlikely to respond to an TNFi therapies. Directing a patient to the correct therapy can limit the wasted time and costs of TNFi cycling, which is associated with substantial disease progression among those who fail to respond adequately.6
How are results of PrismRA reported?
PrismRA gives you actionable results sorted into easy-to-interpret categories that predict a patient’s likelihood of non-response to TNFi medications: Very high: ≥95% likelihood of non-response; High: ≥90% likelihood; No Signal: Molecular signal of non-response not detected. Reports will be delivered via fax.
Will using PrismRA improve therapeutic response rates for my patients?
When modeled, PrismRA can improve patient response rates collectively for TNF inhibitor therapies and alternative MOA therapies by up to 38% by accurately stratifying patients prior to starting or changing therapy.7